CEO Leon Moulder Jr. Discloses 5.09% Beneficial Ownership, Confirming Recent Share Purchases
ZBIO has more than doubled off its 52-week low of $8.51.
Summary
Zenas BioPharma's CEO, Leon O. Moulder Jr., along with affiliated entities, filed a Schedule 13D disclosing a 5.09% beneficial ownership stake, which includes recent open-market purchases.
Key Events · Ownership and Investor Activity · ZBIO
-
CEO's Beneficial Ownership
Leon O. Moulder Jr., through direct and affiliated holdings, beneficially owns 3,220,880 shares, representing 5.09% of the company's common stock.
-
Recent Share Purchases Confirmed
The filing confirms the Reporting Persons purchased an aggregate of 271,000 shares in open-market transactions between January 7 and April 29, 2026, at prices ranging from $15.82 to $19.58 per share.
-
Reinforces Prior Disclosure
This 13D provides a comprehensive overview of the CEO's total beneficial ownership, building on the recent Form 4 filing that reported a significant purchase by Mr. Moulder on April 29, 2026.
Analysis · ZBIO · Life Sciences
This Schedule 13D filing confirms that CEO and Chairman Leon O. Moulder Jr., through his direct holdings and affiliated entities (Tellus BioVentures, LLC and a revocable trust), beneficially owns 5.09% of Zenas BioPharma's common stock. The filing details recent open-market purchases of 271,000 shares between January 7 and April 29, 2026, reinforcing the CEO's confidence in the company. This follows a previous Form 4 filing on April 29, 2026, which reported a specific purchase by Mr. Moulder. The aggregation of these holdings and the establishment of the 5% beneficial ownership threshold provide a comprehensive view of the CEO's significant and growing stake, which can be interpreted as a strong positive signal for investors, especially given the company's recent positive Phase 3 results and ongoing efforts to address a going concern warning.
At the time of this filing, ZBIO was trading at $20.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $8.51 to $44.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.